
Miami, Florida— The International Society for Stem Cell Application (ISSCA), a recognized leader in regenerative medicine education and certification, continues to solidify its global influence by expanding strategic alliances and fostering collaboration among top medical professionals worldwide. With a legacy spanning over 15 years, representation in more than 35 countries, and a network of experts across multiple specialties, ISSCA remains committed to delivering cutting-edge regenerative medicine education and therapies, reinforcing its role as a pioneer in the field.
ISSCA’s remarkable trajectory has positioned it at the forefront of regenerative medicine. This sustained global outreach has enabled the organization to cultivate a Scientific Advisory Board composed of distinguished leaders who bring diverse perspectives and specialties to the field. By integrating insights from experts in interventional pain management, vascular surgery, biohacking, anti-aging, and trauma care, ISSCA ensures a comprehensive and forward-thinking approach to advancing regenerative medicine.
In an era where regenerative medicine is rapidly evolving, ISSCA recognizes the importance of continuously expanding its network to include new thought leaders and innovators. This strategy reflects the organization’s commitment to staying ahead of emerging trends and incorporating the latest advancements into its educational programs. ISSCA’s experts include figures such as Dr. Scott Martin (USA), an authority in interventional pain management; Dr. Vincenzo Di Donna (Italy), a renowned vascular surgeon; Dr. Adam Boender (USA), an expert in biohacking and regenerative therapies; Frederick and Mercedes Kweh (USA), specialists in personalized regenerative medicine; and Dr. Roni Moya (Portugal), a leader in aesthetic and regenerative medicine.
“ISSCA aims to break down barriers and make regenerative medicine accessible globally,” said Benito Novas, Vice President of ISSCA and Global Stem Cells Group. “Our extensive global experience and the diversity of our Scientific Advisory Board are key drivers of this mission. By collaborating with top physicians and researchers from various regions and specialties, we are building a robust foundation for the future of medicine. Our commitment to scientific rigor and excellence empowers physicians to deliver the most advanced and effective cellular therapies to their patients.”
ISSCA’s experts, including Dr. Tarek Sultan (Dubai), a pioneer in pain management; Dr. Joy Kong (USA), a triple board-certified physician specializing in anti-aging; and Dr. Adeel Khan (Canada), a leader in longevity therapies, contribute significantly to ISSCA’s excellence in education and clinical practice. These collaborations are expected to enable ISSCA to provide physicians with access to advanced protocols, hands-on training, and global networking opportunities.
The rapid growth of regenerative medicine has introduced numerous groundbreaking therapies and influential experts, making it essential for ISSCA to continuously expand its advisory board and strategic alliances. By doing so, ISSCA ensures that its educational offerings remain at the forefront of medical innovation. This proactive approach allows ISSCA to integrate the latest scientific insights, fostering a community of professionals dedicated to improving patient outcomes through regenerative therapies.
Through these strategic initiatives, ISSCA aims to elevate the standards of regenerative medicine, empowering medical professionals to enhance patient care with innovative therapies. By leveraging knowledge from diverse regions and specialties, ISSCA is shaping the future of medicine and ensuring that regenerative therapies reach more patients worldwide. This ongoing commitment to excellence reinforces ISSCA’s position as a leading institution in cellular therapies and regenerative medicine.
ISSCA invites medical professionals to join this global movement and participate in the transformative advancements in regenerative medicine.
Learn more and register for upcoming certifications: issca.com
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.
About Global Stem Cells Group
Founded by Benito Novas, Global Stem Cells Group seeks to advance the field of regenerative medicine globally. With a robust presence across continents, the organization provides both treatments and educational programs aimed at empowering doctors, researchers, and patients. Through ISSCA, GSCG conducts specialized training, certification, and hands-on workshops designed to promote best practices in the application of cellular therapies.
For more information about the Dubai clinic opening, ISSCA training event, or Global Stem Cells Group, please visit the Global Stem Cells Group website.
Global Stem Cells Group is a publicly traded company operating under the symbol RMTG. https://finance.yahoo.com/quote/RMTG/
To learn more about Global Stem Cells Group, Inc.’s companies, visit our website www.stemcellsgroup.com or call +1 305 560 5331.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.